Rationalizing the development of live attenuated virus vaccines

Development of an Attenuated Live Virus Vaccine against Sheep Pox

Arenavirus Genome Rearrangement for the Development of Live Attenuated Vaccines.

UNLABELLED Several members of the Arenaviridae family cause hemorrhagic fever disease in humans and pose serious public health problems in their geographic regions of endemicity as well as a credible biodefense threat. To date, there have been no FDA-approved arenavirus vaccines, and current antiarenaviral therapy is limited to an off-label use of ribavirin that is only partially effective. Are...

Live Attenuated Vaccines: Influenza, Rotavirus and Varicella Zoster Virus

Since vaccinia virus was first used to protect against smallpox in the eighteenth century, live attenuated vaccines have proved to be highly effective in reducing the morbidity and mortality caused by many human viral pathogens. Contemporary live viral vaccines are designed using several different strategies to achieve attenuation. These basic principles and approaches are illustrated by vaccin...

Development of a New Live Attenuated Mumps Virus Vaccine in Human Deploid Cells

Live Attenuated Measles Mumps and Rubella Vaccines:

Abbreviations: MMR: Measles, Mumps and Rubella; WHO: World Health Organization; SSPE: Subacute Sclerosing Panencephalitis; PAHO: Pan American Health Organization; CRS: Congenital Rubella Syndrome; MR: Measles-Rubella; GSK: GlaxoSmithKline; EZ: Edmonston Zagreb; CEF: Chicken Embryo Fibroblast; IBD: Inflammatory Bowel Disease; CDC: Centers for Disease Control and Prevention; SSPE: Subacute Sclero...